# Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

> **NCT03867084** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 959 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03867084
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-28
- **Primary completion:** 2025-03-20
- **Final completion:** 2025-09-30
- **Target enrollment:** 959 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867084, "Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03867084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*